AI assistant
Sending…
Spyre Therapeutics, Inc. — Director's Dealing 2017
Feb 16, 2017
32226_dirs_2017-02-16_96a201cb-bc80-4278-8d4a-6f36159c8544.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Aeglea BioTherapeutics, Inc. (AGLE)
CIK: 0001636282
Period of Report: 2017-02-15
Reporting Person: Bruhn Suzanne Louise (Director)
More from Spyre Therapeutics, Inc.
Regulatory Filings
2026
Jun 1
Declaration of Voting Results & Voting Rights Announcements
2026
May 29
Regulatory Filings
2026
May 5
Interim / Quarterly Report
2026
May 5
Regulatory Filings
2026
Apr 16
Capital/Financing Update
2026
Apr 13
Regulatory Filings
2026
Apr 13
Regulatory Filings
2026
Apr 13
Proxy Solicitation & Information Statement
2026
Apr 10
Major Shareholding Notification
2026
Mar 27